Alleima (ALLEI) Q4 2024 earnings summary

Executive summary

• Organic revenue grew 1% for the full year and 3% in Q4, with stable earnings and a strong financial position despite a weaker macro environment and mixed market sentiment.

• Oil and gas, nuclear, and medical segments showed strong performance, while electrification, renewable energy, and Europe were weaker.

• Strategic initiatives included reopening the SGT facility, Kanthal expansion in Japan, establishing a medical footprint in Malaysia, and acquiring Endox.

• The board proposed a dividend of SEK 2.36 per share, a 15% increase, with a payout ratio of 37% of net profit adjusted for metal price effects; some sources report SEK 2.30 per share.

• Solid backlog and positive momentum in several customer segments entering 2025.

Financial highlights

• FY 2024 revenues were SEK 19,691 million (down from SEK 20,669 million in FY 2023); Q4 revenues were SEK 5,094 million, up 1% year-over-year.

• Adjusted EBIT for Q4 was SEK 584 million with an 11.5% margin; full year margin was 9.9%, above the 9% target.

• Free operating cash flow for FY 2024 was SEK 1,266 million; Q4 was SEK 202 million, both lower than last year due to higher CapEx and lower earnings.

• Net debt to equity at -0.04, indicating a net cash position of SEK 1.9 billion at year-end.

• Adjusted EPS (diluted) for FY 2024 was SEK 6.27; Q4 was SEK 1.79.

Outlook and guidance

• Market conditions remain mixed, with positive trends in several customer segments and continued uncertainty in others, especially Europe.

• CapEx guidance for 2025 is SEK 1.2 billion, with maintenance CapEx around SEK 400 million.

• Currency effects expected to be positive SEK 85 million on operating profit in Q1 2025; metal price effect expected to be neutral.

• Tax rate guidance lowered to 23%-25% for 2025.

• Product mix expected to remain similar to Q4; cash flow typically lower in the first half of the year.